科研之友
微信
新浪微博
Facebook
分享链接
摘要
objective: describe the efficacy and safety of tenofovir. methods: observational, descriptive study. data were analyzed for the intention-to-treat sample. the primary efficacy end-point included the proportion of patients with hiv-1 rna level of 50 copies/ml or less. secondary efficacy end points was the increase of the cd4 cell count at week 48. the primary safety end-point was the number of patients with abnormalities (clinical adverse events and laboratory toxicities). the causality of the adverse effects was measured by the naranjo algorithm results: 154 subjects were enrolled; 12 were excluded from all analyses. efficacy end points: plasma hiv-1 rna response: -1.29 ㊣ 0.97 log10 copies/ml; patients with hiv-1 rna levels of 50 copies/ml or less: 28.16%; cd4 cell count response: 40.27 ㊣ 141.50 cel/mm3. safety profile was similar to showed at prescribing information, 3 fanconi syndrome were detected. conclusion: tenofovir supposes an antiretroviral of high effectiveness in our hospital, with an optimum safety profile.
